Sign in

CIK 0001789972

  • Non-accelerated filer
  • Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813879991
Phone
+1 617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Grant or award Chief Financial Officer acquired 47,000 shares (grant or award)
  2. 4 Grant or award Chief Business Officer acquired 20,500 shares (grant or award)
  3. 4 Grant or award Chief Legal Officer acquired 47,000 shares (grant or award)
  4. 4 Grant or award Chief Scientific Officer acquired 38,500 shares (grant or award)
  5. 4 Grant or award Chief Development Officer acquired 38,500 shares (grant or award)
  6. 4 Grant or award Chief Medical Officer acquired 60,000 shares (grant or award)
  7. 5 Insider Annual Insider Trading Report
  8. 4 Other disposition 10% owner disposed of 6,400,000 shares (other)
  9. 4 Grant or award Chief Financial Officer acquired 201 shares (grant or award)
  10. 4 Open-market sale Michaelson Jennifer sold 4,000 shares at $13.30 ($53,200)
  11. 4 Derivatives Options or other derivatives
  12. 3 Insider Initial Statement of Ownership
  13. 4 Open-market sale Michaelson Jennifer sold 4,000 shares at $12.40 ($49,600)
  14. 4 Derivatives Options or other derivatives
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market sale Chief Development Officer sold 1,385 shares at $15.01 ($20,789)
  17. 4 Open-market sale 10% owner sold 49,910 shares at an average $14.26 ($711,676)
  18. 4 Open-market sale Chief Development Officer sold 8,000 shares at $14.51 ($116,080)
  19. 4 Open-market sale Acting Chief Business Officer sold 20,000 shares at an average $15.18 ($303,593)
  20. 4 Open-market sale Acting Chief Business Officer sold 40,000 shares at an average $13.33 ($533,304)

Page 8 of 13 · 253 filings